Forge Biologics, a manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, has announced an agreement with Fractyl Health to support the development and production of its Rejuva* pancreatic gene therapy platform. The therapy is being developed
FAMAR, a portfolio company of private equity investor MidEuropa, has agreed to acquire a sterile manufacturing site in Homburg (Saar), Germany, from MiP Pharma. The move enhances FAMAR’s position in the CDMO sector by strengthening its capabilities in high-value dosage
In the fast-paced world of pharmaceuticals, the race to bring new drugs to market is more competitive than ever. Sponsored by Almac The traditional drug development process, segmented into distinct linear phases, can be time-consuming and costly. However, integrating drug
CellFE has announced a strategic collaboration with Made Scientific, a cell therapy CDMO, to generate pilot-scale data using the High Volume Cyva System. The initiative aims to validate CellFE’s non-viral microfluidics-based gene editing platform for use in both activated and resting T
Benuvia Operations, LLC, a U.S.-based global CDMO and API supplier, today announced it has entered a multi-year supply agreement with a leading U.S. pharmaceutical company. Under the terms, Benuvia will deliver its Dronabinol API to support the customer’s product development
Recipharm, a global contract development and manufacturing organisation (CDMO), has entered into a strategic collaboration with ProductLife Group (PLG), a provider of regulatory and product development services, to streamline the path to market for (bio)pharmaceutical companies. The agreement aims to accelerate
Gil Roth, president of the Pharma and Biopharma Outsourcing Association (PBOA), delivered a stark assessment of the uncertain regulatory and trade environment facing US drug manufacturers under Donald Trump’s administration at CDMO Live 2025. In a presentation characterised by its
eXmoor Pharma, a cell and gene therapy CDMO with embedded consultancy expertise, has entered a strategic partnership with KU Leuven to accelerate novel gene therapy programmes from academic research to first-in-human trials. The collaboration supports KU Leuven’s new cell and
Novopor Advanced Science Private Limited, a CDMO focused on performance chemicals and material science, has acquired Pressure Chemical Company, a U.S.-based provider of high-pressure and specialty chemistry services. The financial details of the acquisition were not disclosed. The deal aligns
Piramal Pharma Limited has announced a $90 million investment to expand two of its manufacturing sites in the United States, aligning with growing demand for domestic drug production and the trend toward onshoring pharmaceutical supply chains. The investment was revealed in
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
